HER2 is overexpressed and/or amplified in about 20% of breast cancers. HER2 positivity signifies an aggressive tumor; however, it also opens the door for targeted therapeutic options. In advanced or metastatic disease, a patient’s prognosis has greatly improved with the emergence of new anti-HER2 therapies. With the addition of these newer treatment options, physicians have a multitude of therapies to choose from, but patient-specific characteristics and sequencing still present a challenge.
In this interactive simulation, clinicians will be mentored through 2 different case-based examinations and will have the opportunity to make patient-specific treatment selections and manage treatment-related adverse events. Find out what changes you can make in your practice today to benefit your patients with HER2-positive metastatic breast cancer.
Since the recording of this interview, additional data have been released specific to efficacy in certain patient subgroups. To learn more about this data, please visit: https://www.bloomberg.com/press-releases/2021-12-09/enhertu-fam-trastuzumab-deruxtecan-nxki-additional-analyses-further-reinforce-ground-breaking-efficacy-in-patients-with-her2